SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule, Inc. (ARQL)
ARQL 20.000.0%Jan 16 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: former_pgs4/30/2005 4:53:12 PM
  Read Replies (1) of 545
 
Interesting tidbit from the 10Q, with numbers in 1000s.

"While we cannot state the internal costs incurred for each of our oncology programs on a program-by-program basis, the expenses incurred by us to third parties for preclinical and clinical trials since inception of each program were as follows (in thousands):"


Oncology program	  Current status	  	  2005-to-date	  	  Program-to-date
ARQ501                    Phase 1	  	           $492	  	  	   $2,476
550 series                Preclinical	  	           —	  	  	   $83
650 series                Preclinical	  	        $756	  	        $1,035


One of the reasons i sold just after the previous quarterly report was due to a perceived lack of progress for 550, which is the second compound under the Roche collaboration. While I realize that external expenses are not a perfect indicator of the level of work / progress on a project, the 550 program appears to be sticking out like a sore thumb.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News